The state of the art of adeno-associated virus-based vectors in gene therapy

Virology Journal

Volumn 4, Issue , 2007, Pages

  Coura, Renata Dos Santos ^a   Nardi, Nance Beyer ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR;

CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; GENETIC DISORDER; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENO ASSOCIATED VIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; METHODOLOGY;

ADENO-ASSOCIATED VIRUS;

DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS;

EID: 36749033228     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-99     Document Type: Review

References (48)

1. Serologic evidence for human infection with adenovirus-associated viruses. NR Blacklow MD Hoggan WP Rowe, J Natl Cancer Inst 1968 40 319 327 4295610
2. Biology of adeno-associated virus. KI Berns C Giraud, Curr Top Microbiol Immunol 1996 218 1 23 8794242
3. Self-complementarity of terminal sequences within plus or minus strands of adenovirus-associated virus DNA. FJ Koczot BJ Carter CF Garon JA Rose, Proc Natl Acad Sci USA 1973 70 215 219 4509654 10.1073/pnas.70.1.215
4. Parvovirus replication. K Berns, Microbiol Rev 1990 54 316 329 2215424
5. Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. T-H Ni WF McDonald I Zolotukhin T Melendy S Waga B Stillman N Muzyczka, J Virol 1998 72 2777 2787 9525597
6. Molecular biology of adeno-associated viruses. RM Linden KI Berns, Contrib Microbiol 2000 4 68 84 10941571
7. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. RJ Samulski KI Berns M Tan N Muzyczka, Proc Natl Acad Sci USA 1982 79 2077 2081 6281795 10.1073/pnas.79.6. 2077
8. Cloning of infectious adeno-associated virus genomes in bacterial plasmids. CA Laughlin JD Tratschin H Coon BJ Carter, Gene 1983 23 65 73 10.1016/0378-1119(83)90217-2 6352411
9. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue cultured cells. PL Hermonat N Muzyczka, Proc Natl Acad Sci USA 1984 81 6466 6470 6093102 10.1073/pnas.81.20.6466
10. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. KI Berns TC Pinkerton GF Thomas MD Hoggan, Virology 1975 68 556 560 10.1016/0042-6822(75)90298-6 1198930
11. The cryptic life style of adeno-associated virus. KI Berns RM Linden, Bioessays 1995 17 237 245 10.1002/bies.950170310 7748178
12. The genetics of adeno-associated virus. N Muzyczka RJ Samulski P Hermonat A Srivastava KI Berns, Adv Exp Med Biol 1984 179 151 161 6098150
13. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. GP Gao MR Alvira L Wang R Calcedo J Johnston JM Wilson, Proc Natl Acad Sci USA 2002 99 11854 1189 12192090 10.1073/pnas.182412299
14. Clades of Adeno-associated viruses are widely disseminated in human tissues. G Gao LH Vandenberghe MR Alvira Y Lu R Calcedo X Zhou JM Wilson, J Virol 2004 78 6381 6388 15163731 10.1128/JVI.78.12.6381-6388.2004
15. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. JF Wright G Qu C Tang JM Sommer, Curr Opin Drug Discov Devel 2003 6 174 178 12669452
16. Observed incidence of tumorigenesis in longterm rodent studies of rAAV vectors. A Donsante C Vogler N Muzyczka JM Crawford J Barker T Flotte M Campbell-Thompson T Daly MS Sands, Gene Ther 2001 8 1343 1346 10.1038/sj.gt.3301541 11571571
17. AAV serotype 2 vectors preferentially integrate into active genes in mice. H Nakai E Montini S Fuess TA Storm M Grompe MA Kay, Nat Genet 2003 34 297 302 10.1038/ng1179 12778174
18. AAV loves an active genome. DW Russell, Nat Genet 2003 34 241 242 10.1038/ng0703-241 12833043
19. Advances in AAV-mediated gene transfer for the treatment of inherited disorders. M Hildinger A Auricchio, Eur J Hum Genet 2004 12 263 271 10.1038/sj.ejhg.5201153 14722585
20. Gene therapy: promises and problems. A Pfeifer IM Verma, Annu Rev Genomics Hum Genet 2001 2 177 211 10.1146/annurev.genom.2.1.177 11701648
21. A realistic chance for gene therapy in the near future. S Worgall, Pediatr Nephrol 2005 20 118 124 10.1007/s00467-004-1680-0 15549408
22. Clinical trial database. http://www.wiley.co.uk/genetherapy/clinical/
23. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. JA Wagner AH Messner ML Moran R Daifuku K Kouyama JK Desch S Manley AM Norbash CK Conrad S Friborg T Reynolds WB Guggino RB Moss BJ Carter JJ Wine TR Flotte P Gardner, Laryngoscope 1999 109 266 274 10.1097/00005537-199902000-00017 10890777
24. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. JA Wagner IB Nepomuceno AH Messner ML Moran EP Batson S Dimiceli BW Brown JK Desch AM Norbash CK Conrad WB Guggino TR Flotte JJ Wine BJ Carter TC Reynolds RB Moss P Gardner, Hum Gene Ther 2002 13 1349 1359 10.1089/104303402760128577 12162817
25. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. ML Aitken RB Moss DA Waltz ME Dovey MR Tonelli SC McNamara RL Ginson BW Ramsey BJ Carter TC Reynolds, Hum Gene Ther 2001 12 15 1907 1916 10.1089/104303401753153956 11589832
26. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. RB Moss D Rodman LT Spencer ML Aitken PL Zeitlin D Waltz C Milla AS Brody JP Clancy B Ramsey N Hamblett AE Heald, Chest 2004 125 509 521 10.1378/chest.125.2.509 14769732
27. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. MA Kay CS Manno MV Ragni PJ Larson LB Couto A McClelland B Glader AJ Chew SJ Tai RW Herzog V Arruda F Johnson C Scallan E Skarsgard AW Flake KA High, Nat Genet 2000 24 257 261 10.1038/73464 10700178
28. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. H Jiang LB Couto S Patarroyo-White T Liu D Nagy JA Vargas S Zhou CD Scallan J Sommer S Vijay F Mingozzi KA High GF Pierce, Blood 2006 108 3321 3328 10.1182/blood-2006-04-017913 16868252
29. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. TR Flotte ML Brantly LT Spencer BJ Byrne CT Spencer DJ Baker M Humphries, Hum Gene Ther 2004 15 93 128 10.1089/1043034041361190 14965381
30. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. P Leone CG Janson L Bilaniuk Z Wang F Sorgi L Huang R Matalon R Kaul Z Zeng A Freese SW McPhee E Mee MJ During, Ann Neurol 2000 48 27 38 10.1002/1531-8249(200007)48:1<27::AID-ANA6>3.0. CO;2-6 10894213
31. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. C Janson S McPhee L Bilaniuk J Haselgrove M Testaiuti A Freese DJ Wang D Shera P Hurh J Rupin E Saslow O Goldfarb M Goldberg G Larijani W Sharrar L Liouterman A Camp E Kolodny J Samulski P Leone, Hum Gene Ther 2002 13 1391 1412 10.1089/104303402760128612 12162821
32. Immune responses to AAV in a phase I study for Canavan disease. SW McPhee CG Janson C Li RJ Samulski AS Camp J Francis D Shera L Lioutermann M Feely A Freese P Leone, J Gene Med 2006 8 577 588 10.1002/jgm.885 16532510
33. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. RG Crystal D Sondhi NR Hackett SM Kaminsky S Worgall P Stieg M Souweidane S Hosain L Heier D Ballon M Dinner K Wisniewski M Kaplitt BM Greenwald JD Howell K Strybing J Dyke H Voss, Hum Gene Ther 2004 15 1131 1154 15610613
34. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. MJ During MG Kaplitt MB Stern D Eidelberg, Hum Gene Ther 2001 12 1589 1591 11529246
35. Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. JA Wagner IB Nepomuceno N Shah AH Messner ML Moran AM Norbash RB Moss JJ Wine P Gardner, J Gene Med 1999 1 13 21 10.1002/(SICI)1521-2254(199901/02)1:1<13::AID-JGM6>3.3.CO;2-7 10738581
36. Evaluation of exposure and health care worker response to nebulized administration of tgAAVCF to patients with cystic fibrosis. GA Croteau DB Martin J Camp M Yost C Conrad PL Zeitlin AE Heald, Ann Occup Hyg 2004 48 673 681 10.1093/annhyg/meh066 15507460
37. Adeno-associated virus vectors in clinical trials. BJ Carter, Hum Gene Ther 2005 16 541 550 10.1089/hum.2005.16.541 15916479
38. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. DM McCarty PE Monahan RJ Samulski, Gene Ther 2001 8 1248 1254 10.1038/sj.gt.3301514 11509958
39. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. DM McCarty H Fu PE Monahan CE Toulson P Naik RJ Samulski, Gene Ther 2003 10 2112 2118 10.1038/sj.gt.3302134 14625565
40. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Z Wang HI Ma J Li L Sun J Zhang X Xiao, Gene Ther 2003 10 2105 2111 10.1038/sj.gt.3302133 14625564
41. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. H Fu J Muenzer RJ Samulski G Breese J Sifford X Zeng DM McCarty, Mol Ther 2003 8 911 917 10.1016/j.ymthe.2003.08.021 14664793
42. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. GS Yang M Schmidt Z Yan JD Lindbloom TC Harding BA Donahue JF Engelhardt R Kotin BL Davidson, J Virol 2002 76 7651 7660 12097579 10.1128/JVI.76.15.7651-7660.2002
43. Delivery of MDR1 small interfering RNA by self-complementary recombinant adenoassociated virus vector. D Xu D McCarty A Fernandes M Fisher RJ Samulski RL Juliano, Mol Ther 2005 11 523 530 15771955 10.1016/j.ymthe.2004.12.019
44. AAV hybrid serotypes: improved vectors for gene delivery. VW Choi DM McCarty RJ Samulski, Curr Gene Ther 2005 5 299 310 15975007 10.2174/ 1566523054064968
45. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. N Muzyczka KH Warrington Jr, Hum Gene Ther 2005 16 408 416 10.1089/hum.2005.16.408 15871672
46. Intravitreal injection of adeno-associated viral vectors results in the transduction of different types of retinal neurons in neonatal and adult rats: a comparison with lentiviral vectors. AR Harvey W Kamphuis R Eggers NA Symons B Blits S Niclou GJ Boer J Verhaagen, Mol Cell Neurosci 2002 21 141 157 10.1006/mcne.2002.1168 12359157
47. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. T Vandendriessche L Thorrez A Acosta-Sanchez I Petrus L Wang L Ma L DE Waele Y Iwasaki V Gillijns JM Wilson D Collen MK Chuah, J Thromb Haemost 2007 5 16 24 10.1111/j.1538-7836. 2006.02220.x 17002653
48. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. P Manilla T Rebello C Afable X Lu V Slepushkin LM Humeau K Schonely Y Ni GK Binder BL Levine RR MacGregor CH June B Dropulic, Hum Gene Ther 2005 16 17 25 10.1089/hum.2005.16.17 15703485